Faruqi & Faruqi Alerts uniQure Investors: Class Action Deadline Approaching

Deadline Alert for uniQure Investors

Faruqi & Faruqi, LLP, a preeminent national securities law firm, is actively probing potential claims against uniQure N.V. (NASDAQ: QURE) as part of a federal securities class action. Investors who purchased or obtained shares in uniQure between September 24, 2025, and October 31, 2025, should take note of a critical deadline—April 13, 2026. This date marks the last opportunity for eligible investors to move to become lead plaintiffs in the ongoing litigation.

The firm encourages affected investors to reach out directly to Senior Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). In the aftermath of recent disclosures regarding the Pivotal Study outcomes of uniQure's AMT-130 trial, the share price saw a staggering drop. The company initially portrayed positive perspectives regarding its products; however, claims were made that the study's design faced FDA scrutiny and lacked full approval, compromising the validity of previous statements by uniQure executives.

Faruqi & Faruqi is well-versed in securities law and has recovered substantial amounts for harmed investors since its establishment in 1995. The firm is investigating allegations that uniQure's management made misleading statements regarding the approval process for AMT-130, which potentially misled investors about the company’s financial forecast and operational integrity.

Allegations Against uniQure

The complaint centralizes on several critical allegations:
1. Misleading Statements: The firm argues that uniQure’s management failed to disclose that the study’s design did not enjoy full FDA endorsement, thus presenting a flawed image of the company's position in the market.
2. Downplayed Risks: Key executives downplayed the risks associated with the likelihood of delaying the BLA (Biologics License Application) timeline, which raised concerns among investors about the company’s real standing.
3. False Assurances: Statements previously made by the defendants lacked substantial grounds, as the potential of AMT-130 achieving accelerated approval was later contradicted by FDA communications.

In a troubling update on November 3, 2025, uniQure revealed that the FDA would no longer consider the data from its studies adequate for the anticipated BLA submission. Consequently, this admission caused uniQure’s share price to plummet by more than 49%, from an October 31 close of $67.69 to a stark $34.29 by November 3, severely impacting investors financially.

What Investors Should Do

For those who purchased shares within the specified timeframe, it is crucial to assess the potential legal options available and determine if moving forward as a lead plaintiff is the right course of action. Even if an investor chooses not to seek this designation, they remain eligible to partake in any financial recovery available to class members. The committee for lead plaintiff selection would focus on an individual who can best represent the interests of all injured investors.

Additionally, any whistleblowers, former employees, or others with insight into uniQure's operations are encouraged to contact Faruqi & Faruqi as their information could be vital for the ongoing investigation.

For further information or to follow updates related to the class action, interested parties can visit Faruqi & Faruqi’s dedicated webpage or reach out directly. As always, communication will be treated with confidentiality to protect the interests of all parties involved.

By joining this class action, investors are taking proactive steps to ensure that their rights are protected and that they receive potential redress for their financial losses. Don’t let the deadline pass—act now to secure your position in this significant legal proceeding.